Search results
Results from the WOW.Com Content Network
The Moderna news followed preliminary results from the Pfizer-BioNTech vaccine candidate, BNT162b2, with Moderna demonstrating similar efficacy, but requiring storage at the temperature of a standard medical refrigerator of 2–8 °C (36–46 °F) for up to thirty days or −20 °C (−4 °F) for up to four months, whereas the Pfizer-BioNTech ...
The CDC’s new COVID-19 vaccine recommendations suggest a second dose of the updated COVID-19 vaccine for people who are 65+, as well as those who are moderately or severely immunocompromised ...
The CDC has recommended seniors receive a second dose of the 2023-2024 COVID-19 vaccine, depending on when their last vaccine or infection took place.
National regulatory authorities have granted full or emergency use authorizations for 40 COVID-19 vaccines.. Ten vaccines have been approved for emergency or full use by at least one stringent regulatory authority recognized by the World Health Organization (WHO): Pfizer–BioNTech, Oxford–AstraZeneca, Sinopharm BIBP, Moderna, Janssen, CoronaVac, Covaxin, Novavax, Convidecia, and Sanofi ...
All new Pfizer and Moderna vaccines target the Omicron variant KP.2 strain of SARS-CoV-2, the virus that causes COVID. Spikevax, the COVID-19 vaccine manufactured by Moderna and FDA-approved for ...
A US soldier holding the Pfizer–BioNTech vaccine. Pfizer and BioNTech are manufacturing the vaccine in their own facilities in the United States and in Europe. The license to distribute and manufacture the vaccine in China was purchased by Fosun, alongside its investment in BioNTech. [47] [137] Manufacturing the vaccine requires a three-stage ...
"It's OK to mix and match Moderna and Pfizer," Dr. Ralph Gonzales, associate dean for clinical innovation and chief innovation officer for UC San Francisco, said at a campus town hall last week.
On February 26, 2015, ACIP voted to deliver a Category A recommendation for administering MenB vaccines to persons older than 10 years who were at higher risk of meningococcal disease. On June 24, 2015, ACIP heard the arguments for recommending Pfizer and Novartis's serogroup B meningococcal vaccines for everyone in the 16-22 age group.